Edition:
United Kingdom

Affimed NV (AFMD.OQ)

AFMD.OQ on NASDAQ Stock Exchange Global Market

2.05USD
23 Feb 2018
Change (% chg)

$-0.10 (-4.65%)
Prev Close
$2.15
Open
$2.15
Day's High
$2.20
Day's Low
$2.05
Volume
52,541
Avg. Vol
84,968
52-wk High
$2.92
52-wk Low
$1.17

Chart for

About

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its... (more)

Overall

Beta: --
Market Cap(Mil.): $96.98
Shares Outstanding(Mil.): 43.26
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Affimed Announces Proposed Public Offering Of Common Stock

* AFFIMED ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

12 Feb 2018

BRIEF-Affimed Reports New Data For AFM13 From Two Separate Clinical Trials

* AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE CLINICAL TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS

01 Feb 2018

BRIEF-Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash

* Affimed presents data from Phase 1B combination study of AFM13 with Pembrolizumab at Ash

11 Dec 2017

BRIEF-Affimed reports Q3 loss per share EUR 0.18

* Q3 earnings per share view EUR -0.17 -- Thomson Reuters I/B/E/S

07 Nov 2017

BRIEF-Affimed announces Q3 financial results and corporate update conference call

* Affimed announces third quarter 2017 financial results and corporate update conference call Source text for Eikon: Further company coverage:

30 Oct 2017

Earnings vs. Estimates